Spain agrees to reimburse Sativex for MS
This article was originally published in Scrip
Executive Summary
Spain has become the second country to reimburse the cannabinoid drug Sativex for treating multiple sclerosis-related spasticity. GW Pharmaceuticals developed and manufactures the drug, which is marketed by Almirall in Europe, except in the UK where Bayer has the marketing rights.